ZNTL vs PRAX vs ARVN vs FOLD

For growth investors, Amicus Therapeutics, Inc.

(FOLD) is the stronger pick with 20. 0% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Analysts rate Zentalis Pharmaceuticals, Inc. (ZNTL) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Amicus Therapeutics, Inc.

(FOLD) delivered a total return of +36. 4%, compared to -93. 7% for Zentalis Pharmaceuticals, Inc. (ZNTL). Over 10 years, the gap is even starker: FOLD returned +147. 3% versus ZNTL's -83. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.

(FOLD) is the lower-risk stock at 0. 48β versus Zentalis Pharmaceuticals, Inc. 's 2. 26β — meaning ZNTL is approximately 369% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Amicus Therapeutics, Inc.

(FOLD) is pulling ahead at 20. 0% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Arvinas, Inc. grew EPS 53. 8% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, ARVN leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zentalis Pharmaceuticals, Inc.

(ZNTL) is the more profitable company, earning 0. 0% net margin versus -30. 8% for Arvinas, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FOLD leads at 5. 4% versus -43. 8% for ARVN. At the gross margin level — before operating expenses — ARVN leads at 98. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ZNTL: 184.

1% to $10. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Amicus Therapeutics, Inc.

(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48), +147. 3% 10Y return). Zentalis Pharmaceuticals, Inc. (ZNTL) carries a higher beta of 2. 26 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FOLD: +147. 3%, ZNTL: -83. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ZNTL is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; ARVN is a small-cap quality compounder stock; FOLD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.